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Abstract 
 
KAYLEE GRACE HOLMES: A Study of the Antioxidant Versus Pro-oxidant Nature of 
the Amyloid Beta Peptide and an Analysis of the Natural Products, Isorhamnetin and 
Naringenin, as Antioxidants 
 
(Under the direction of Dr. Saumen Chakraborty) 
 
Alzheimer’s disease is a neurodegenerative disorder with no cure. Due to the 
widespread effects of this disease, abundant research efforts have gone towards finding a 
cure. The amyloid beta (Ab) peptide has been shown to be a potential cause of the disease 
due to destructive effects on tissues that it can have both by itself and through reactive 
oxygen species (ROS) generation. This study was performed in order to assess the 
structural properties of Ab42 monomers, fibrils and oligomers, to assess the antioxidant 
versus pro-oxidant behavior of the Ab peptide, and to assess the antioxidant nature of the 
natural products isorhamnetin and naringenin. Several different ROS assays were 
performed in order to gain insight into the nature of Ab42, isorhamnetin, and naringenin.  It 
was found that the oligomeric form of the peptide behaved solely as a pro-oxidant and 
generated much more ROS than the monomers and fibrils. The monomers and fibrils, 
however, showed antioxidant behavior as they decreased the amount of ROS generated by 
free copper under oxidative conditions.  Isorhamnetin was far more successful at reducing 
ROS generation in all forms of the peptide than naringenin. After performing a copper 
titration, it was determined that two isorhamnetin molecules are able to bind one copper. 
These results indicate that Ab42 oligomers behave as pro-oxidants while Ab42 monomers 
and fibrils behave as antioxidants. The results also indicate that isorhamnetin is a better 
antioxidant than naringenin. 
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Chapter 1: Introduction 
 
1.1 Alzheimer’s Disease 
Worldwide, the leading cause of dementia is Alzheimer’s Disease as 50-80% of all 
dementia cases are due to Alzheimer’s.1 According to the World Health Organization, there 
is approximately 18 million cases of Alzheimer’s worldwide.1 Its development has been 
found mostly in people over the age of 60, yet approximately 5% of all cases occur in 
people under the age of 60.1 The Alzheimer’s disease is a fatal neurodegenerative disease 
meaning there is loss of structure and function of the nerve cells that will eventually lead 
to death.2 The type of nerve cells specifically affected in Alzheimer’s are those of the 
cerebral cortex.2 Due to the fact that there is no known cure for Alzheimer’s Disease, it is 
not surprising that there is considerable research going towards finding a cure.1 
The greatest risk factor in Alzheimer’s Disease is increased age, and with humans 
progressively living longer, Alzheimer’s Disease is becoming more and more prevalent.1 
In the next 20 years, the cases of the AD are expected to double, and by the year 2050, 
there is expected to be around 125 million cases of Alzheimer’s disease.1,3 With increasing 
AD cases expected to develop each year, there is also significant cost associated with the 
disease. According to the Alzheimer’s Association and the National Institute on Aging, in 
the United States AD costs about $100 billion dollars annually (both direct and indirect 
costs included).3 However, the invention of new treatments that could delay the onset of 
AD for even just five years would save the US and approximately $50 billion dollars 
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annually.3 Taking into account the fatality of the disease as well as its estimated progression 
and financial burden, it is clear to see why finding a cure for the disease is a priority in the 
world of research.  
 
1.2 The Role of Amyloid Beta in Alzheimer’s Disease 
In Alzheimer’s Disease, there are two distinct pathologies that are found in the brain; 
extracellular plaque deposits of the amyloid-b peptide and the neurofibrillary tangles of the 
micro-tubule binding protein tau.4,5 Although the tau protein does appear to be involved in 
the progression of AD, it is processed downstream of the amyloid-b peptide buildup.6,9 
Amyloid-b has two species: one consisting of 40 amino acids and the other consisting of 
42 amino acids.5 The Ab42 form is believed to be more neurotoxic.8 Amyloid-b is generated 
by the cleavage of the transmembrane amyloid precursor protein (APP), where its N-
terminus originates from the extracellular domain of APP and the C-terminus originating 
from the transmembrane region of APP.5 When mutation occurs in APP, there is either an 
increased production of amyloid-b or an increased proportion of the amyloid-b-42 residue.5 
Many of the mutations in APP have little effect on its functionality but instead cause the 
tendency of amyloid-b to form fibrils.7 Hereditary early onset forms of AD are linked to 
mutations within the amyloid-b precursor protein (AbPP), although these cases make up 
only about 1% of the total cases of AD.1,4 APP undergoes substantial post-translational 
processing which can be in form of glycosylation, phosphorylation, and many other forms 
including various types of proteolytic processing to generate peptide fragments.53 It is most 
commonly cleaved by proteases in the secretase family including alpha, beta, and gamma 
secretases. The alpha and beta secretases work to remove almost the entire extracellular 
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domain in order to release membrane-anchored carboxy-terminal fragments while the 
gamma secretases cleave within the membrane spanning domain.54,55 The cleavage of beta 
secretases followed by the cleavage of gamma secretases leads to the generation of the 
amyloid peptide.55 The cleavage of APP to form the amyloid-beta peptide is shown below 
in Figure 1. 
 
Figure 1. This figure illustrates the cleavage of APP to form the Ab peptide. Here, the a, b, and g secretases 
work to cleave APP from the membrane as well as to further cleave it into the Ab peptide. The Ab peptide 
is represented by the yellow rectangle and the blue rectangle as well as the black line represent the cleaved 
portions of APP. This process occurs during post-translational processing of APP. 
 
 In searching for the causative agent of AD, Hardy and colleagues published the 
amyloid cascade theory in which they proposed that the deposition of the amyloid-b 
peptide was the causative agent of AD.9,10 With this hypothesis they also proposed that the 
neurofibrillary tangles of the tau protein, cell death, vascular destruction, and dementia 
followed as direct effects of the deposition of the amyloid-b peptide.10 A study was also 
done in which mice were given the human gene for increased levels of Ab42 and it was 
found that they exhibited molecular, cellular and behavioral phenotypes similar to those 
found in AD.11  However, there remain many substantial controversies with this theory. 
The most recurring controversy is the fact that amyloid-b deposits have been found in the 
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brains of humans who did not report or have symptoms of mental derange.6 This 
controversy has been disputed by the fact that the deposits found in many of these subjects 
are of the diffuse type, meaning they do not have fibrillar amyloid, neuritic dystrophy or 
cytotoxiciticty.6 Controversy has also been disputed by the fact that the soluble amyloid-b 
oligomers have not been quantified, and yet the peptide in the soluble oligomeric form is 
what is associated with the progression of AD.6 Also, the subjects who were said to not 
have had signs of dementia (yet still had amyloid plaques), were not studied thoroughly 
enough to be confident whether or not they showed any signs of cognitive impairment.6 In 
fact, it has been observed in seemingly normal subjects with amyloid deposits through 
amyloid-b imaging by positron emission tomography (PET), that there are often some 
cognitive deficiencies in such subjects.6 Lastly, most chronic diseases show significant 
amounts of pathology prior to the diseases earliest symptoms.6 With this being true, 
amyloid-b deposits in the brain cannot be dismissed for being linked to a cascade of 
neurodegeneration characteristic of AD.  
Amyloid-b is a metalloprotein with several metal coordination residues and a 
hydrophobic core. These attributes along with its sequence are depicted below in Figure 
2. Amyloid-b peptide consists in three different structural forms: the monomeric form, the 
fibrillar form and the oligomeric form. Though the oligomeric form is thought to be the 
most toxic form, it is hard to fully distinguish due to its heterogeneous and metastable 
characteristics.10 Originally, amyloid-b was thought to only be toxic in its fibrillar form, 
but when fibril formation was inhibited, neurotoxin formation still occurred.11 The 
neurotoxin that was found was composed of small diffusible amyloid-b oligomers.11 
Because there are other molecules that appear in increased levels in AD affected brains, 
 5 
there is a hypothesis that these molecules act as a chaperone to allow Ab to self-associate, 
causing diffusible oligomers to form which are more harmful than even the fibrillary form 
of the amyloid peptide.11 It was found that small amounts of a senile plaque protein slowly 
produced neurotoxin deposits in the central nervous system (CNS). These deposits were 
made of amyloid-b oligomers which were small, soluble, extremely diffusible, and toxic 
even in dilute nanomolar concentrations to mature CNS neurons.11 This evidence is 
remarkable since one of the initial oppositions to amyloid-b being the causative agent for 
AD was the fact that it took tremendous amounts of the fibrillary form (initially believed 
to be the most toxic form) to kill neuronal cells.12 Since the discovery that Ab oligomers 
were indeed the most toxic form of the Ab peptide, extreme efforts have been made in 
order to try and better understand the complex oligomeric form of Ab on molecular and 
cellular levels.  
 
Figure 2. This figure shows the sequence for the Ab42 peptide. The amino acids highlighted in red indicate 
the metal coordinated residues and the amino acids highlighted in blue indicate the hydrophobic core of the 
peptide. 
 
1.3 Amyloid Beta Oligomers: their pathway and toxicity 
The amyloid peptide is intrinsically disordered meaning it does not have stable 
secondary or tertiary structures.10 It can, however, still become folded or partially folded 
in particular conditions.13 These conditions include conformational variations, pH, 
temperature, concentration of peptide and other external factors.10,13 Due to the fact that 
the oligomeric form of amyloid-b is composed of a heterogenous mixture of intermediates 
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derived from several different pathways, the characterization of the oligomeric form has 
been extremely difficult and complex.10 In addition, the longer Ab residue (Ab42) 
introduces even greater variability (than the other major residue, Ab40) in its monomeric 
and fibrillary forms.15 Atomic Force Microscope (AFM) images showing the different 
morphological features between Ab fibrils and oligomers are shown below in Figure 3.  
 
Figure 3. This figure shows AFM images taken of the A) oligomeric and B) fibrillar forms of the Ab peptide. 
Source: Mitra, Suchitra, Pallavi Prasad, and Saumen Chakraborty. "A Unified View of Assessing the Pro-
oxidant versus Antioxidant Nature of Amyloid Beta Conformers." ChemBioChem 19.22 (2018): 2360-2371.  
 
Before Ab can self-aggregate at all, it first must be cleaved from APP via b- and g- 
secretases. When Ab monomers become partially folded, they tend to interact with one 
another.13,15 This interaction allows their self-recognition sites to come in contact with each 
other and this promotes the beginning of self-aggregation.13,15 This process is actually 
spontaneous because the interactions between these partially folded monomers are strong 
enough to overcome the original desire for disorder in the system. 10,13 Next, oligomeric 
species begin to form. Initially, small, toxic oligomers develop and begin to generate a 
nucleus.10 The diverse, three-dimensional, Ab species found in the nucleation process are 
referred to as on-pathway oligomers. These oligomers are later converted into larger 
aggregates or fibrillary Ab units.13,15 However, deviation from this pathway can occur, and 
the creation of this deviant species of oligomers are referred to as off-pathway oligomers. 
This deviation has been demonstrated by using polyphenol (-)-epigallocatechin gallate 
A B 
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(EGCG) in which EGCG was used to redirect the amyloid pathway and thus eliminate the 
possibility that amyloid fibrils would form.16 Off-pathway oligomers are non-toxic and are 
stable final products unlike on-pathway oligomers which are an intermediary species for 
fibril formation during elongation.16 This multistep process is shown below in Figure 4. 
 
Figure 4. This figure illustrates Ab production and aggregation. (A) Ab production occurs due to the 
cleavage of APP by b- and g-secretases. Natively the Ab peptide is unfolded, but due to both 
environmental and genetic factors, they can become partially folded.  (B) During on-pathway 
oligomerization, Ab forms structured, transient oligomers which are suspected to be toxic. Off- pathway 
oligomers also form and are stabilized without further fibril growth. (C) Structured oligomers are 
metastable intermediates that further transform into protofibrils or fibrils. (D and E) Some fibrils can 
fragment and reassemble into structured oligomers (fragmentation). In addition, structured oligomers 
can be generated through interactions between monomers and fibrils (secondary nucleation).10 
 
Source: Lee, Shin Jung C., et al. "Towards an understanding of amyloid-β oligomers: characterization, 
toxicity mechanisms, and inhibitors." Chemical Society Reviews 46.2 (2017): 310-323. 
 
When Ab monomers interact and aggregation occurs, as described previously, the 
process is called primary nucleation. However, Ab monomers can instead interact with Ab 
fibrils created downstream; this process is referred to as secondary nucleation.17 The 
nucleation phase is the rate-determining step during amyloid fibrillation, with secondary 
nucleation being significantly faster than primary nucleation. When enough fibrils have 
formed to consistently interact with Ab monomers, secondary nucleation becomes the 
dominant pathway for amyloid fibrillization.17 In secondary nucleation, monomer-fibril 
interactions may cause the process of oligomer formation to be catalyzed.17 Fibrils formed 
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through either pathway can dissociate into oligomers under certain stimulus such as force.17 
This is referred to as fibril fragmentation.10 A study performed in 2013, suggested there is 
a positive feedback loop involving secondary nucleation and fibril fragmentation.17 In the 
study, as the oligomeric reservoir grew greater (via fibril fragmentation), secondary 
nucleation was promoted, thereby further increasing the oligomeric reservoir at a faster and 
faster rate.17 Therefore, oligomer formation can be produced through primary nucleation, 
secondary nucleation, and fibril fragmentation, and thus the oligomeric reservoir is 
continually increasing which means the toxicity levels also rapidly increase. This rapid rise 
in toxicity expedites the neurodegeneration in AD, and thus causes increased concern to 
learn how these oligomeric species can be suppressed. 
Because it becoming more and more obvious that soluble, diffusible Ab oligomers 
exhibit neurotoxicity in AD, the mechanisms by which they become toxic has become 
widely studied. There are three major mechanisms in which Ab induces toxicity: 
interaction with membranes and synaptic receptors, intracellular system influence, and 
cell-to-cell transmission.10 Extracellular amyloid-b oligomers can affect the cellular 
membrane in various ways. They can bind the membrane and in doing so cause damaging 
changes to the membrane. They can bind to signal transducing membrane receptors, thus 
either causing the cell to endocytose them, or generate damage due to abnormal signaling. 
They can cause the flow of substances into and out of the cell to be disrupted by penetrating 
the cell with circular structures that they form.  In vivo and in vitro studies have shown that 
there is an interaction between Ab oligomers and lipid rafts (membrane domains consisting 
of cholesterol, GM1-ganglioside sphingolipids, and synaptic receptors.)18 In a study 
performed on Tg2576 transgenic mice, it was found that although the lipid rafts only make 
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up a small portion of total brain volume, they do contain 27% of Ab42 that is found in the 
brain and 24% of Ab40 that is found in the brain.18 Because lipid rafts are involved in signal 
transduction, the accumulation of Ab oligomers on lipid rafts could hinder signal 
transduction causing memory deficits.10 This theory was supported by the Tg2576 
transgenic mice study where the accumulation of Ab on lipid rafts in 6 month on mice 
caused memory decline.18 Other studies suggest that when Ab interacts with membrane 
receptors, that synapse loss is initiated which is believed to be the link between 
neurodegeneration and cognitive impairment.19 This interaction also promotes the 
endocytosis of oligomers, thus triggering further damage to the intracellular systems. 20 As 
previously mentioned, Ab can also be generated and accumulated within the cell. This 
accumulation can cause many processes within the cell to have problems. Accumulation 
could cause stress to the endoplasmic reticulum (ER), calcium ion imbalance, 
mitochondrial damage, altered proteolysis, and ultimately these damages can cause cell 
death.21 The final mechanism in which Ab oligomers become toxic is through cell-to-cell 
transmission. The mechanism by which Ab oligomers spread is very similar to the way 
that prion diseases spread.14 A recent study was conducted in which autopsies of patients 
who had received cadaver-derived growth hormone, showed both the prion disease 
Creutzfeldt–Jakob disease (CJD), and amyloid-b plaque deposits. These patients had no 
genetic mutations linked with hereditary AD. The question arose as to whether or not Ab 
pathology could be transmitted in humans similar to the way prion diseases are by way of 
seeding.14,22 In a study performed on transgenic mice, concentrations of brain samples from 
AD patients were injected into the hippocampal formation or neocortex of the mice.22 After 
a few days of incubation, there was no detectable trace of Ab. However, after 3 to 5 months 
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post injection, Ab deposits appeared and increased drastically the longer they were allowed 
to incubate.22 The degree to which Ab-seeding appeared in the mice was directly 
proportional to the concentrations of the brain samples that were injected into the mice.22 
The mice that had received brain extracts from non-AD infected brains showed no 
significant amounts of Ab deposits.22  The seeding mechanism that is believed to occur 
here is through a system of donor and acceptor neurons. The donor already contains the 
Ab and the acceptor receives Ab from the donor.10,22 In a study performed by Nath and 
colleagues, Ab was fluorescently labeled and was seen to be transferred from donor to 
acceptor cells. Ab42 showed the highest transmission rate out of the various isoforms of 
Ab.22 This cell-to-cell transmission produced large lysosomal vesicles that had the 
potential to dysregulate both the donor and acceptor cells. This is one pathway in which 
Ab is believed to spread within the brain of AD patients.14,22 However, more studies need 
to be performed to truly gain a complete view of Ab transmission.  
 
1.4 The Role of Metals and Reactive Oxygen Species in Alzheimer’s Disease 
The neurodegeneration that takes place in AD is also greatly impacted by the fact that 
Ab is a metalloprotein, meaning that Ab is metal-binding.8 Metals are necessary for 
enzymatic function and often work to catalyze reactions, provide structural stability, and 
they play an important role in cellular signaling.24 Therefore having a healthy balance of 
metals like iron, zinc, and copper, is an essential part of a healthy system.24 However, in 
diseased brains, these concentrations become much higher than what is considered 
healthy.8 Metal dyshomeostasis and abnormalities in the way metals are metabolized are 
thought to be directly involved with neurodegeneration in AD.25 The amount of copper that 
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is deposited in the brain increases with age, but in AD patients this amount increases to 
concentrations as high as ~0.4 mM in the cerebral amyloid deposits.8,23 In healthy cells, 
proteins tightly regulate copper, and no free copper is available because of this.8 However, 
in diseased cells copper becomes unregulated, and hypermetalation occurs in copper 
proteins and Ab peptides.8 In Ab, Cu2+ is believed to bind to His6, His13/His14, the 
terminal amine, an O atom (probably a part of the Ala2 backbone) and O-Asp1.8,25 Under 
aerobic conditions and in the presence of biological reductants (such as ascorbic acid which 
is found at 0.2–10 mM concentrations in the brain), Cu2+ is reduced to Cu+.8 By way of the 
Fenton–Haber–Weiss reaction (shown in Scheme 1), this reduction in copper gives rise to 
reactive oxygen species (ROS), which include O2-, H2O2 and OH•. Although copper bound 
Ab is not the only source for copper reduction, it is the major source and thus accounts for 
the majority of ROS production.8,23 This increase in free radical production leads way to 
an imbalance between the radicals and antioxidants in the body and thus causes oxidative 
stress.26 The proposed structure for the copper-Ab complex is shown in Scheme 1.27 
Copper redox cycling is proposed to occur via a preorganized electron transfer (POET) 
mechanism.28 This mechanism preorganizes the distances and angles within the Ab-Cu 
coordination sphere so that it minimally rearranges upon electron transfer thus lowering 
the reorganization energy by 0.3 eV.28 The POET mechanism leads to greater efficiency in 
redox cycling. The ROS created thorough this cycling oxidize cellular DNA, RNA, 
proteins and lipids, and therefore damage cellular function.30 Lipid peroxidation occurs 
when ROS steal electrons from lipids, and this peroxidation produces 4-hydroxynonenal 
(HNE) which causes cellular damage specifically with cellular signaling.8,29  
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Scheme 1. (A) Proposed Cu2+/Cu+ coordination of Ab; (B) ROS generation by the Fenton-Haber-Weiss 
reaction. 
 
Many studies have been performed to try and better understand Cu-catalyzed ROS 
production. It is still unclear whether Ab plays an antioxidant role31, a pro-oxidant role32, 
or if it can be both an antioxidant and pro-oxidant within Cu-catalyzed ROS production.33 
The reasoning behind the antioxidant role of Ab is due to the fact that in solution, the level 
of free radicals generated by Ab is lower than the amount of free Cu2+.8 The reasoning 
behind the pro-oxidant role of Ab is the fact that the Ab-Cu complex generated more free 
radicals than other copper binding peptides.8 Recent studies have shown that both the 
monomeric and fibrillar forms of Ab can act as radical scavengers decreasing the amount 
of free radicals in vitro.34 It has also been shown that Ab40 fibrils cause redox silencing, 
further deceasing the amount of free radicals.35 Though information about the roles of the 
monomeric and fibrillar forms of Ab has been studied and better understood, not much is 
understood about the role of the oligomeric form. Because the oligomeric form is 
considered the most neurotoxic form, it is important to further understand what role the 
oligomeric form plays in Cu-catalyzed ROS production. 
A) 
B) 
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1.5 The Role of Natural Products in Alzheimer’s Disease Research 
Many studies have suggested that there are dietary factors involved with the occurrence 
of AD, and in response, much research effort has gone towards understanding the influence 
that natural products have on Ab toxicity. Specifically natural products with antioxidant 
properties and the ability to modulate small molecules are being researched as possible 
targets for AD.36 These natural products can chelate metals and regulate metal homeostasis, 
alleviate oxidative stress, interact with Ab both covalently and noncovalently, and redirect 
the Ab aggregation pathway thus lowering the toxicity of potential aggregates.37  
Flavonoids are a family of natural substances containing phenolic structures which are 
commonly found in fruits, vegetables, grains, bark, roots, stems, flowers, tea and wine.44 
Flavonoids are known for their health benefits specifically in regards to their anti-oxidative, 
anti-inflammatory, anti-mutagenic and anti-carcinogenic properties as well as their ability 
to regulate cellular enzymatic function.44  In plants, flavonoids play a role in growth and 
defense against the formation of plaques which has made them very interesting in regards 
to AD research.44 Flavonoids also have been shown to chelate iron and copper ions and 
therefore have been studied in regards to their potential relationship with metal-overload 
diseases as well as in situations regarding oxidative stress.45 In a study performed by 
Holland and colleagues, it was concluded that higher dietary intake of flavanols may 
correspond to a decreased risk of developing dementia or Alzheimer’s Disease.47 
In this experiment, the natural flavonoids isorhamnetin and naringenin were selected 
in order to evaluate their ability to inhibit Cu-Ab42-induced ROS generation and regulation 
of the morphology of the monomeric, oligomeric and fibrillar species of the peptide under 
oxidative stress. Isorhamnetin (structure shown below in Figure 5A) is an O-methylated 
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flavanol. This flavonoid is commonly isolated from water dropwort (Oenanthe javanica, 
Umbelliferae).46 Pears, olive oil, wine, tomato sauce, and Mexican tarragon are also 
sources of isorhamnetin.47,48 It has been shown to have antioxidant, anti-inflammatory, and 
anti-proliferative effects.46 Naringenin (structure shown in Figure 5B) is a flavanone 
commonly found in a variation of fruits and herbs and it is the major flavanone found in 
grapefruit.49,50 This flavanone exists in two forms: the aglycol form (naringenin) and the 
glycosidic form (naringin), with the aglycol form being the most bioavailable.51 Naringenin 
has been shown to have antioxidant effects as it decreases oxidative stress in cells.52  
 
Figure 5. (A) Structure for isorhamnetin; (B) Structure for naringenin. 
 
Studies have been performed on a similar flavonoid, kaempferol (shown below in 
Figure 6), in which kaempferol decreased ROS production in all species of Ab.8  The study 
also demonstrated that two kaempferol molecules bind one Cu2+.8 The study accredited 
kaempferol’s antioxidant abilities to three structural features: 1)its para-hydroxy group on 
its C-ring provides stability to aryloxy radicals through H bonding and takes part in electron 
dislocation, 2) its 2,3-double bond and 4-oxo group on its B-ring contribute to electron 
dislocation, 3) its  3- and 5-hydroxy groups that stabilize electron density from the C-ring.8 
We predicted that isorhamnetin and naringenin would behave in a similar way due to their 
similar structures. Isorhamnetin is structurally the same as kaempferol except for its added 
A) 
B) 
A B 
C C 
B A 
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methoxy group, and naringenin structurally the same as kaempferol except it is missing a 
hydroxy group on its B-ring.  
 
Figure 6. Structure for kaempferol. 
  
A B 
C 
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Chapter 2: Methods 
 
2.1 Synthesis and Purification of the Amyloid-b-42 Peptide  
Synthesis 
In this experiment, Ab42 (NH3+–Ab42-CONH2) was synthesized using an automated 
microwave peptide synthesizer (Liberty Blue, CEM). This was done on a 0.1 millimolar 
scale using Rink Amide Pro-Tide Resin (CEM) with a poly(ethylene glycol) poly styrene 
backbone. In this study, the C-terminal amide was used because it tends to increased 
biological stability as well as an increased shelf-life. The coupling steps were performed at 
90 ºC for 4 minutes. All amino acids (Advanced Chemtech) were weighed in 
concentrations of 0.2 M and dissolved in dimethylformamide (DMF; VWR). The activator 
base used was 1 M Oxyma (CEM) and the activator used was 0.5 M N,N’-
diisopropylcarbodiimide (DIC; Advanced Chemtech) in DMF. The deprotection solution 
used was 20% piperidine (Advanced Chemtech) in DMF. Starting at His14, residues were 
double-coupled to guarantee that all amino acids were present in the synthesized peptide. 
Histidine residues were coupled at 50 ºC  for 10 minutes to ensure that no racemization 
occurred.  
Cleavage 
 In order to cleave the peptides from the resin and side-chain deprotection, the 
synthesized product was treated with 92.5% trifluoroacetic acid (TFA; Advanced 
Chemtech), 0.25% triisopropylsilane (TIS; Sigma–Aldrich), 0.25% ethane-1,2-dithol 
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(EDT; Sigma–Aldrich), and 0.25% water, in 10 mL volume. The product was treated for 2 
hours at room temperature with continuous stirring. After cleavage, the crude peptides were 
filtered, and excess TFS was evaporated under a low flow of nitrogen gas. The crude 
peptides were then precipitated, washed with cold diethyl ether, dissolved in 10% acetic 
acid, and lyophilized. Then, the peptides were dissolved a second time in 10% acetic acid. 
After the peptides were dissolved in acetic acid, the peptides were ready for purification 
via High Performance Liquid Chromatography (HPLC). 
High Performance Liquid Chromatography 
 Using a C18-semiprep column (1260 Infinity II HPLC system, Agilent), the peptide 
was purified. The column compartment was kept at 75 ºC. A linear gradient from Solvent 
A (0.1% TFA in H2O) to Solvent B (90% acetonitrile, 10% H2O, 0.1% TFA) was used. 
Next, the peptide was injected at 1 mL•min-1 and eluted with 90% A and 10 % B for 5 
minutes followed by a linear gradient to 70% B over 25 minutes at a flow rate of 4 mL•min-
1. The peptide was eluted at about 50-60% Solvent B. The elution of the peptide was 
monitored via a chromatogram at 214 and 280 nm. The purified peptide was then 
lyophilized and stored in its monomeric form.  
 
2.2 Preparation of Peptide Stocks 
 The purified and lyophilized peptide (1mM) was dissolved in 1,1,1,3,3,3-
hexafluoropropan-2-ol (HFIP). These treated peptides were then placed in Eppendorf tubes 
(caps kept open) and left under the hood overnight. Next, the tubes were lyophilized in 
order to create films of completely unaggregated peptides. These peptides were kept at -80 
ºC and used as needed.  
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 In order to create a usable monomeric form of the peptide stocks, 100 µL of freshly 
made 10 mM NaOH (made from a freshly prepared 1 M NaOH stock) was placed into an 
Eppendorf tube containing the lyophilized and purified peptide (dissolved in HFIP). This 
tube was then vortexed for 30 seconds. After being vortexed, the tube was sonicated for 10 
minutes at room temperature. Finally, the tube was centrifuged at 15000 g And room 
temperature for 3 minutes and immediately transferred to ice. The final concentrations of 
the monomeric peptides were then determined in cold water with an Agilent 8454 UV/Vis 
spectrophotometer by using  Beer’s Law (Equation 1) where e280=1490 M-1cm-1. Water 
with 10 mM NaOH was used as the blank. 
 
2.3 Preparation of Amyloid-b-42 Fibrillar and Oligomeric Forms 
Fibrillar Form 
 The fibrillar form of the peptide was prepared using premade monomeric peptides 
of known concentrations (as discussed in Section 2.3). Ab monomers were mixed with 
phosphate buffered saline (PBS; pH 7.4) to achieve a fibril concentration of 100 µM. Once 
the PBS was added to the monomer, the tube was then incubated for 24 hours at 37 ºC. 
Figure 7B, shown below, depicts this preparation.  
Oligomeric Form 
 The oligomeric form of the peptide was also prepared using premade monomeric 
peptides of known concentrations (as discussed in Section 2.3). To achieve a final 
concentration of 25 µM, Ab monomers were mixed with PBS (pH 7.4). Next, the mixture 
was centrifuged for 30 minutes at 15000 g and room temperature. Once the centrifugation 
was complete, the supernatant was taken from the tube and the pellet was disposed of. The 
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supernatant was then sonicated for 1 minute at room temperature. Once sonication was 
complete, the capped tube was allowed to sit at room temperature for 24 hours before being 
used experimentally. Figure 7A, shown below, depicts this preparation. 
 
Figure 7. This figure depicts the methods of preparation of A) oligomers and B) fibrils used in this 
experiment. 
 
2.4 Confirmation of Peptide Purity using MALDI-TOF MS 
 The identity and purity of the synthesized peptide stock was confirmed using 
MALDI-TOF MS (Bruker Voyager) with sinapinic acid (Sigma–Aldrich, 10 mg•mL-1 
stock in ACN/H2O (50:50) with 0.1% TFA) as the matrix. Using a ProteoMass calibration 
kit (Sigma-Aldrich) the instrument was externally calibrated. The sample, which contained 
a 1:1 ratio of peptide to matrix, was then loaded onto a MALDI plate and analyzed.  
 
2.5 Preparation of Reagents 
 All buffer solutions were prepared in Milli-Q (Millipore) water and treated with 
Chelex 100 (Bio Rad) overnight to ensure that no trace metals remained in solution. The 
following day, the buffer was filtered using a buffer filter. The 1mM copper chloride stock 
solution (Alpha Aesar) was made in the presence of 40 mM glycine (Sigma-Aldrich) in 
order to prevent the precipitation of copper phosphate in the solution.  This copper 
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chloride/glycine solution was the source of copper throughout the experiment. The ascorbic 
acid 10 mM stock solution (VWR) was prepared fresh daily in water. The 10 mM 
coumarin-3-carboxylic acid (3-CCA; Acros Organics) stock solution was prepared in 
phosphate buffer (PB; 20 mM; pH 9.0) at room temperature, and then was stored at -20 ºC. 
Prior to use, the 3-CCA was diluted with PB, and using either NaOH or H3PO4 the solution 
was adjusted to a pH of 7.4. The stock solutions of naringenin and isorhamnetin were 
dissolved in DMSO to a 7 mM concentration. The 10 mM Amplex Red stock solution was 
prepared in DMSO and stored at -20 ºC. The horseradish peroxidases (HRP) stock solutions 
were prepared at 10 Uml-1 in PB (pH 7.4).  
 
2.6 Cu2+ Binding to Isorhamnetin  
 A Cu2+ binding titration of isorhamnetin was performed using an Agilent Cary 8454 
UV-Vis spectrophotometer in a 1 cm path-length quartz cuvette. The solutions consisted 
of isorhamnetin (20 µM) in HEPES buffer (pH 7.4) with 1% DMSO added to the solution. 
For the blank scan, DMSO was substituted for the natural products in the solution. Cu2+ 
was added in 0.1 equivalent increments and was allowed to stir for 15 minutes before taking 
the measurement. When the UV-Vis spectra ceased to change, the Cu2+ had saturated the 
natural product and the titration was complete. Using the UV-Vis spectra, absorbance at an 
initial major peak l versus the equivalents of copper added was plotted in order to 
determine how many equivalents of copper was necessary to saturate isorhamnetin. 
Though the same experiment was intended to be performed for naringenin, lab restrictions 
prohibited it from being conducted.  
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2.7 UV-Vis ASC Assay 
 
UV-Vis spectroscopy is a widely used analytical method, most often utilized for its 
quantitative applications. It is commonly used to determine the concentration of analyte in 
solution by utilizing Beer’s Law which is shown below in Equation 1. 
A=ebc 
Equation 1. This equation represents Beer’s Law where A is equal to the absorbance, e is equal to the molar 
extinction coefficient, b is equal to the path length and c is equal to the concentration of the analyte.39 
 
A beam of UV and visible radiation is sent through a cuvette containing the sample. 
The sample solution then absorbs the light. How the sample absorbs the light is dependent 
on the concentration of the sample as well as the samples ability to absorb certain 
wavelengths of light. A detector, on the other side of the cuvette, is able to capture the 
amount of light that passes through the sample (this light was not absorbed by the 
sample).40 The resulting data given by the UV-Vis spectrometer is the absorbance of light 
given at specific wavelengths. In order for UV-Vis spectroscopy to be used to analyze a 
sample, the sample must be known to absorb light within the UV or Visible region of the 
electromagnetic spectrum. In this region of the spectrum , electrons undergo electronic 
transitions. Common compounds that absorb in this region are transition metal ions, highly 
conjugated organic compounds, and biological macromolecules.40  
 In this study the kinetics of ascorbic acid (ASC) oxidation was monitored using an 
Agilent Cary 8454 UV-Vis spectrophotometer in a 1 cm path-length quartz cuvette. The 
decay of the ASC peak was monitored at 265 nm. The samples contained Ab (5 µM), Cu2+ 
(4.5 µM), ASC (100 µM), naringenin (90 µM) and isorhamnetin (90µM). Chelated 
 22 
phosphate buffer was added to the samples to reach a final volume of 320 µL. The 
composition of the samples that were used for analysis are shown below in Table 1.  
 
 Contents of the Sample 
Sample 1 Ab (monomer, oligomer, or fibril), ASC 
Sample 2 Ab (monomer, oligomer, or fibril), Cu2+, 
ASC 
Sample 3 Ab (monomer, oligomer, or fibril), 
naringenin, ASC 
Sample 4 Ab (monomer, oligomer, or fibril), Cu2+, 
naringenin, ASC 
Sample 5 Ab (monomer, oligomer, or fibril), 
isorhamnetin, ASC 
Sample 6 Ab (monomer, oligomer, or fibril), Cu2+, 
isorhamnetin, ASC 
Sample 7 Cu2+, ASC 
Table 1. This table shows the composition of each of the samples involved in the ASC assay. These samples 
were run individually for the monomeric, fibrillar, and oligomeric species of the Ab peptide. 
 
All components of the samples were mixed prior to the addition of ASC to ensure 
Cu2+ binding. Each sample (without ASC) was placed into the cuvette and a background 
reading was taken. The ASC was then added to the cuvette and mixed via pipette mixing. 
Immediately following the addition of ASC, the analysis was started. The UV-Vis 
spectrophotometer was set to take a reading once every 60 seconds for a total of 3300 
seconds. Each experiment was performed at least three times with different preparations of 
each Ab species (monomers, oligomers, and fibrils).  
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2.8 Fluorescence Hydroxyl Radical Assay 
Fluorescence spectroscopy is a type of electromagnetic spectroscopy that analyzes 
the fluorescence given off by a sample. It uses a beam of light, usually ultraviolet, to excite 
the electrons in a molecule and the excitation causes them to emit light.41 The molecule is 
first excited through the absorption of a photon, from its ground electronic state to a 
vibrational state in the molecules excited electronic state.42 When the excited molecule 
collides with other molecules, it loses vibrational energy until it reaches the lowest 
vibrational state possible within that excited electronic state.42 This process is shown in a 
Jablonski diagram.42  
In this experiment, the Cu-Ab species was probed to produce OH•  by the Fenton-
Haber-Weiss Reaction using a colorimetric CCA-3 assay. The kinetics of the oxidation of 
3-CCA to the fluorescent molecule, 7-hydroxycoumarin-3-carboxylic acid (7-OH-CCA) , 
by the hydroxyl radical, OH•, were monitored. This was done using a PTI fluorimeter with 
the lexcitation set at 395 nm and the lemission set at 450 nm. These wavelengths are where the 
fluorescent molecule, 7-OH-CCA, can be detected. The samples contained Ab peptides (10 
µM), Cu2+ (9µM), 3-CCA (100 µM) and ASC (100 µM). Chelated phosphate buffer was 
added to the samples to reach a final volume of 320 µL. These assays were performed at a 
2:1 Ab/Cu2+ ratio. The natural products (isorhamnetin and naringenin) were not analyzed 
in this assay because they were dissolved in DMSO which can scavenge OH• and thus alter 
results.43 The composition of the samples that were used for analysis are shown below in 
Table 2.  
 
 Contents of the Sample 
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Sample 1 Ab (monomer, oligomer, or fibril), CCA, 
ASC 
Sample 2 Ab (monomer, oligomer, or fibril), Cu2+, 
CCA, ASC 
Sample 3 Cu2+, CCA, ASC 
Table 2. This table shows the composition of each of the samples involved in the OH• assay. These samples 
were run individually for the monomeric, fibrillar, and oligomeric species of the Ab peptide. 
 
 All components of the samples were mixed prior to the addition of ASC. 
Each sample (without ASC) was placed into the cuvette and a background emission scan 
was taken. The ASC was then added to the cuvette and mixed via pipette mixing. 
Immediately following the addition of ASC, the analysis was begun. The fluorimeter was 
set to obtain one scan every 60 seconds for 3000 seconds. Each experiment was performed 
at least three times with different preparations of each Ab species (monomers, oligomers, 
and fibrils).  
 
2.9 UV-Vis H2O2 Assay 
An Agilent Cary 8454 UV-Vis spectrophotometer in a 1 cm path-length quartz 
cuvette was used to monitor the Cu2+-catalyzed H2O2 formation. In the presence of HRP, 
Amplex Red reacts with H2O2 to produce the chemical resorufin, and therefore resorufin 
was monitored as a direct measure of the relative amount of H2O2 produced.8 Resorufin 
absorbs strongly at 572 nm.8 The samples for the H2O2 assays with peptides consisted of 
Ab (5 µM), Cu2+ (4.5 µM), Amplex Red (50 µM), HRP (0.1 UmL-1), ASC (100 µM), 
naringenin (90 µM), isorhamnetin (90µM), and 1% DMSO which was added to the samples 
in order to ensure that the natural products remained soluble. Chelated phosphate buffer 
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was added to the samples to reach a final volume of 320 µL. The composition of the 
samples that were used for analysis are shown below in Table 3.  
 
 Contents of the Sample 
Sample 1 Ab (monomer, oligomer, or fibril), 
Amplex Red, HRP, DMSO, ASC 
Sample 2 Ab (monomer, oligomer, or fibril), Cu2+, 
Amplex Red, HRP, DMSO, ASC 
Sample 3 
Ab (monomer, oligomer, or fibril), 
naringenin, Amplex Red, HRP, DMSO, 
ASC 
Sample 4 
Ab (monomer, oligomer, or fibril), Cu2+, 
naringenin, Amplex Red, HRP, DMSO, 
ASC 
Sample 5 
Ab (monomer, oligomer, or fibril), 
isorhamnetin, Amplex Red, HRP, DMSO, 
ASC 
Sample 6 
Ab (monomer, oligomer, or fibril), Cu2+, 
isorhamnetin, Amplex Red, HRP, DMSO, 
ASC 
Sample 7 Cu2+, Amplex Red, HRP, DMSO, ASC 
Table 3. This table shows the composition of each of the samples involved in the H2O2 assay. These samples 
were run individually for the monomeric, fibrillar, and oligomeric species of the Ab peptide. 
 
All components of the samples were mixed prior to the addition of ASC to ensure 
Cu2+ binding. Each sample (without ASC) was placed into the cuvette and a background 
reading was taken. The ASC was then added to the cuvette and mixed via pipette mixing. 
Immediately following the addition of ASC, the analysis was begun. The production of 
H2O2 was monitored at 572 nm. The UV-Vis spectrophotometer was set to take a reading 
once every 60 seconds for a total of 3300 seconds. Each experiment was performed at least 
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three times with different preparations of each Ab species (monomers, oligomers, and 
fibrils).  
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Chapter 3: Results and Discussion 
 
3.1 Confirmation of Peptide Purity using MALDI-TOF MS  
 HPLC was performed in order to purify the peptide after synthesis. The HPLC 
chromatogram is shown below in Figure 8.  
 
 
Figure 8. This figure shows the chromatogram that was generated by HPLC during purification. (A) This 
plot was monitored at 280 nm where  tyrosine can be observed. Because Ab42 contains tyrosine, it can be 
monitored to indicate the presence of Ab42 during HPLC. The peak at approximately 18.5 minutes indicates 
the purified peptide. (B) This plot was monitored at 215 nm where the peptide bond can be observed. This 
peak also occurred at approximately 18.5 minutes and is therefore where the peptide was collected. 
 
After HPLC purification was complete, MALDI-MS was used to verify that purity 
of the peptide. Using  MALDI-MS, the spectrum shown in Figure 9 was found for the 
purified Ab peptide. A strong peak at 4513 m/z emerged which corresponds to the 
molecular weight of the Ab42 peptide which is 4514 Da.38 This spectrum ensures that 
following HPLC, that the peptide was purified and ready to be used experimentally.  
A 
B 
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Figure 9. MALDI-MS of the purified Ab peptide stock. The strong peak at 4513 m/z corresponds to the 
molecular weight of the Ab peptide. 
 
3.2 Cu2+ Binding to Isorhamnetin 
 The ability of isorhamnetin to chelate Cu2+ and scavenge ROS generated by Cu-
Ab species was monitored in this experiment. First, titration was used to monitor this. 
Gradual amounts of Cu2+ were added to the isorhamnetin solution and spectra changes 
were observed until saturation was reached and no further changes occurred. This spectra 
is shown below in Figure 10. Two major peaks at 271 nm and 378 nm and one minor 
peak at 321 nm from isorhamnetin decayed and eventually two new major peaks at 252 
nm and 319 nm formed as isorhamnetin became saturated with copper.  This indicates 
that isorhamnetin successfully binds copper. 
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Figure 10. UV/Vis spectra of Cu2+ binding titration to a solution containing 10 µM isorhamnetin in 20 mM 
HEPES buffer (pH 7.4). The starting isorhamnetin spectrum is shown in blue. Subsequent spectra from Cu2+ 
binding are shown in less intense red, with the final Cu-isorhamnetin spectrum shown as thick red. The 
disappearance and emergence of major peaks are shown as blue and red arrows, respectively. The star is 
placed directly above the isosbestic point on the plot which indicates the wavelength at which the absorbance 
did not change throughout the course of the experiment. 
 By plotting the absorbance peak at 378 nm against the equivalents of Cu2+ added, 
it was found that 0.5 equivalents of copper binds to 1 equivalent of isorhamnetin (Figure 
11). Unfortunately this titration was unable to be repeated due to laboratory restrictions 
caused by COVID-19. Ideally, there would be no decrease in slope after the saturation 
point at 0.5 equivalents.  
 
Figure 11. This figure shows absorbance at 378 nm (where a major peak decayed) versus the equivalents of 
copper added. The sample reaches complete saturation at approximately 0.5 equivalents of copper where the 
slope of the line ceases to decrease drastically. Therefore, 0.5 equivalents of copper is needed to bind one 
equivalent of isorhamnetin. In other words, 2 isorhamnetin molecules are needed to bind 1 copper.  
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Kaempferol, a compound with a similar structure to isorhamnetin is believed to 
bind 1 copper with 2 kaempferol molecules. This bond is formed between the two 
hydroxyl groups on ring B (shown in Figure 6) on two different kaempferol molecules 
(four hydroxyl groups total) to one copper molecule. Because the saturation ratio is the 
same for isorhamnetin to copper, Figure 12 proposes a potential way in which 
isorhamnetin binds copper.  
 
Figure 12. This figure proposes a way in which 2 equivalents of isorhamnetin could bind 1 equivalent of 
copper.  
 
 Though isorhamnetin seems like it may work equal to kaempferol as an 
antioxidant, isorhamnetin also has a potentially pro-oxidant feature. Due to the addition 
of a methoxy group on ring C (as compared to kaempferol), it is believed that this 
electron donating group may give electrons to Cu2+ causing Cu+ to be stabilized. 
A B 
C 
A B 
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According to the Fenton-Haber-Weiss reaction (shown in Scheme 1B), Cu+ leads to ROS 
generation and therefore this portion of isorhamnetin is believed to also exhibit pro-
oxidant behavior.  
Ideally, this titration would have also been performed for naringenin, but due to lab 
restrictions caused by COVID-19, this was not possible.  
 
3.3 UV-Vis ASC Assay 
 In this experiment, ASC oxidation was used as a direct measure of the amount of 
ROS produced by different species of the Ab peptide. This was performed using 10 µM 
peptide and 9 µM Cu2+ in the presence of tenfold excess of ASC. ASC oxidation was 
monitored over the course of 3000 seconds by the decay of an absorbance peak at 265 nm. 
The oligomeric form of Ab (Figure 13B) consumed ASC the fastest compared to the 
monomeric form, fibrillar form, and free Cu. This indicates that the oligomeric form 
generates more ROS in a shorter amount of time.  
 To test the effect of isorhamnetin and naringenin on ASC oxidation, they were 
added with a tenfold excess with respect to Cu2+ to the different species of the Ab peptide. 
Naringenin did not show much decrease in the generation of ROS production, instead it 
only slightly decreased the ROS production in the monomeric form of the peptide, but not 
in any of the other forms. Isorhamnetin moderately decreased the amount of ROS produced 
in all species of the Ab peptide as shown by the royal blue line in Figure 13. It reduced 
ROS production the most for the fibrillar form of the peptide as seen in Figure 13C. 
Compared to a study performed by Chakraborty and colleagues using the natural product 
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kaempferol, the natural products isorhamnetin and naringenin are not as effective at 
reducing ROS production as kaempferol.8   
 
Figure 13. In this figure, as ASC is consumed, less absorbance is detected. Here, ASC consumption is used 
as a direct measure of ROS production. (A) Ab monomer, (B) Ab oligomer, (C) Ab fibril. 
 
3.4 Fluorescence Hydroxyl Radical Assay 
 Using a colorimetric 3-CCA assay, the ability of each Cu-Ab species to produce 
OH• by the Fenton-Haber-Weiss reaction was assessed. Consistent with the ASC oxidation 
and H2O2 experiments, the oligomeric form of the peptide showed the highest rate of OH• 
production compared to the monomeric and fibrillar forms of the peptide. This can be seen 
in Figure 14, where the red line in Figure 14B increases more than the red line in Figure 
14A (monomer) and Figure 14C (fibril). In all cases the amount of OH• produced by free 
Cu2+ (shown by the turquoise line in Figure 14) was much greater than the amount 
produced by the Cu-Ab complex. The lower amount of OH• produced by the monomeric 
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and fibrillar forms of the peptide suggest that they effectively scavenge OH• , and thus 
hinder the production of the fluorescent molecule, 7-OH-CCA. Therefore, these forms of 
the peptide appear to behave as antioxidants against radicals. The increased production of 
OH• in this study along with the increase in ROS production in both the ASC and H2O2 
assays indicates that the oligomeric form acts as a pro-oxidant. The differences in OH• 
production between each of the Ab species indicates that there are inherent differences in 
the structure of their Cu binding complexes which changes the efficiency of electron 
transport and thus the amount of ROS produced also is affected.  
 
Figure 14. This figure shows the production of the fluorescent molecule 7-OH-CCA, thus indicating that 
OH• radical was produced. The higher the intensity on the plot, the more OH• was produced. (A) Ab 
monomer, (B) Ab oligomer, (C) Ab fibril. 
 
3.5 UV-Vis H2O2 Assay 
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 The relative amounts and rates of H2O2 production by each Ab species was 
monitored in this assay by the detection of resorufin at 572 nm. The data retrieved is 
shown below in Figure 15. The oligomeric form of the peptide produced substantial 
amounts of H2O2 with the absorbance shown to reach about 1.2. The monomeric form of 
the peptide produced less than the oligomeric form of the peptide with its maximum 
absorbance shown to reach about 0.8. The fibrillar form of the peptide, generated far less 
H2O2 with its maximum absorbance only reaching half of what the oligomeric form did 
(about 0.6). The monomeric and oligomeric forms of the Cu-Ab complex showed to 
produce more H2O2 than free Cu2+. This was only substantial for the oligomeric form 
since about two times the amount of H2O2 was generated for the Cu-AbO complex than 
was generated for free Cu2+ in solution. This confirms the pro-oxidant role of the 
oligomeric form of the peptide. Though the Cu-AbM complex showed to generate more 
H2O2 than free Cu2+ it was not major at all, and thus does not imply a pro-oxidant role of 
the monomeric form, and does not negate the antioxidant properties shown in the ASC 
oxidation assay. The fibrillar form showed a substantial decrease in H2O2 production 
compared to that produced by free Cu2+ in solution, therefore confirming the antioxidant 
role of the fibrillar form demonstrated in the ASC oxidation assay. 
 Isorhamnetin showed a substantial decrease in the amount of H2O2 production in 
all forms of the peptide, with in all cases the amount of H2O2 produced being less than 
that of even just Ab in solution (without Cu2+). Naringenin, however, showed minimal 
decrease in H2O2 production. Overall, in both the ASC oxidation study and in the H2O2 
study, isorhamnetin was much better at decreasing ROS production than naringenin. 
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Figure 15. Top left: Monomer, Top Right: Oligomer, Bottom: Fibril 
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Chapter 4: Conclusion 
This study was performed in order to assess the structural properties of Ab42 
monomers, fibrils and oligomers, to assess the antioxidant versus pro-oxidant behavior of 
the Ab peptide, and to assess the antioxidant nature of the natural products isorhamnetin 
and naringenin.  
First, the synthesis and purification of Ab42 was performed, and then the 
purification of the peptide was evaluated using MALDI-MS. After retrieving the purified 
peptide, monomers, oligomers, and fibrils were all prepared. Several different assays 
were performed using all forms of the peptide as well as in some cases the natural 
products naringenin and isorhamnetin.  
The first assay performed was an ASC assay performed on a UV-Vis 
spectrometer (Figure 13). It was found that the oligomeric form of the peptide generated 
more ROS in a shorter amount of time than the other forms, as it to be expected. It was 
also found that naringenin did not show a major decrease in the generation of ROS 
production. Isorhamnetin, on the other hand, did moderately decrease the amount of ROS 
produced in all species of the Ab peptide, with the most decrease occurring in the fibrillar 
form.  
The second assay performed was fluorescence hydroxyl radical assay. The 
purpose of this assay was to determine which form of the peptide behaved most as a pro-
oxidant as well as to verify the antioxidant nature of the monomeric and fibrillar forms of 
the peptide. This experiment was successful as it can be seen in Figure 14 that the 
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oligomeric form produced considerably more hydroxyl radical than the other two forms 
of the peptide.  
The final assay that was performed was an H2O2 assay performed on a UV-Vis 
spectrometer. This assay monitored the relative amount of H2O2 produced upon the 
presence of ASC in the sample. This experiment showed similar results to the ASC assay.  
The oligomeric form of the peptide produced considerably more amounts of H2O2 than 
the other forms of the peptide. Isorhamnetin showed a major decrease in the amount of 
H2O2 production in all forms of the peptide, with in all cases the amount of H2O2 
produced being less than that of even just Ab in solution (without Cu2+). Naringenin, 
however, showed minimal decrease in H2O2 production. 
Overall it was found that isorhamnetin was drastically more effective in 
decreasing ROS species than naringenin. This was shown in both the ASC and H2O2 
assays. In order to determine the binding capability of isorhamnetin to copper, a copper 
binding titration was performed with isorhamnetin and it was found that 1 equivalent of 
isorhamnetin binds 0.5 equivalents of copper. In other words, 2 isorhamnetin molecules 
were needed to bind one copper molecule. The proposed isorhamnetin-copper complex is 
shown in Figure 12.  
The results of this study indicate that Ab42 oligomers behave as pro-oxidants 
while Ab42 monomers and fibrils behave as antioxidants. The results also indicate that 
isorhamnetin is a better antioxidant than naringenin. 
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